🇺🇸 FDA
Pipeline program

Anti-CDH17 CAR-T cells infusion

BG-CT-22-013

Phase 1 mab active

Quick answer

Anti-CDH17 CAR-T cells infusion for CDH17-positive Advanced Solid Tumors is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
CDH17-positive Advanced Solid Tumors
Phase
Phase 1
Modality
mab
Status
active

Clinical trials